全文获取类型
收费全文 | 574篇 |
免费 | 41篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 6篇 |
妇产科学 | 6篇 |
基础医学 | 67篇 |
口腔科学 | 1篇 |
临床医学 | 55篇 |
内科学 | 195篇 |
皮肤病学 | 9篇 |
神经病学 | 35篇 |
特种医学 | 26篇 |
外科学 | 30篇 |
综合类 | 8篇 |
预防医学 | 104篇 |
眼科学 | 5篇 |
药学 | 18篇 |
中国医学 | 1篇 |
肿瘤学 | 47篇 |
出版年
2023年 | 8篇 |
2022年 | 11篇 |
2021年 | 24篇 |
2020年 | 14篇 |
2019年 | 18篇 |
2018年 | 17篇 |
2017年 | 12篇 |
2016年 | 12篇 |
2015年 | 11篇 |
2014年 | 23篇 |
2013年 | 37篇 |
2012年 | 54篇 |
2011年 | 41篇 |
2010年 | 25篇 |
2009年 | 24篇 |
2008年 | 39篇 |
2007年 | 33篇 |
2006年 | 35篇 |
2005年 | 45篇 |
2004年 | 26篇 |
2003年 | 15篇 |
2002年 | 27篇 |
2001年 | 6篇 |
2000年 | 3篇 |
1999年 | 7篇 |
1998年 | 7篇 |
1997年 | 3篇 |
1996年 | 2篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 8篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1988年 | 1篇 |
1986年 | 1篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1972年 | 2篇 |
1971年 | 1篇 |
1968年 | 2篇 |
1967年 | 1篇 |
排序方式: 共有617条查询结果,搜索用时 31 毫秒
611.
612.
Roberta Bovenzi Giulia Maria Sancesario Matteo Conti Piergiorgio Grillo Rocco Cerroni Jacopo Bissacco Paolo Forti Emilia Giannella Massimo Pieri Silvia Minosse Valentina Ferrazzoli Noemi Pucci Mario Laudazi Roberto Floris Francesco Garaci Mariangela Pierantozzi Alessandro Stefani Nicola Biagio Mercuri Eliseo Picchi Francesca Di Giuliano Tommaso Schirinzi 《European journal of neurology》2023,30(7):1983-1990
613.
Jorge Camacho Estela Giménez Eliseo Albert Joao Zulaica Beatriz Álvarez-Rodríguez Ignacio Torres Luciana Rusu Javier S. Burgos Salvador Peiró Hermelinda Vanaclocha Ramón Limón María Jesús Alcaraz José Sánchez-Payá Javier Díez-Domingo Iñaki Comas Fernando Gonzáles-Candelas Ron Geller David Navarro the Valencian Vaccine Research Program study group 《Journal of medical virology》2023,95(1):e28284
Studies investigating the cumulative incidence of and immune status against SARS-CoV-2 infection provide valuable information for shaping public health decision-making. A cross-sectional study on 935 participants, conducted in the Valencian Community (VC), measuring anti-SARS-CoV-2-receptor binding domain-RBD-total antibodies and anti-Nucleocapsid (N)-IgGs via electrochemiluminescence assays. Quantitation of neutralizing antibodies (NtAb) against ancestral and Omicron BA.1 and BA.2 variants and enumeration of SARS-CoV-2-S specific-IFNγ-producing CD4+ and CD8+ T cells was performed in 100 and 137 participants, respectively. The weighted cumulative incidence was 51.9% (95% confidence interval [CI]: 48.7–55.1) and was inversely related to age. Anti-RBD total antibodies were detected in 97% of participants; vaccinated and SARS-CoV-2-experienced (VAC-ex; n = 442) presented higher levels (p < 0.001) than vaccinated/naïve (VAC-n; n = 472) and nonvaccinated/experienced (UNVAC-ex; n = 63) subjects. Antibody levels correlated inversely with time elapsed since last vaccine dose in VAC-n (Rho, −0.52; p < 0.001) but not in VAC-ex (rho −0.02; p = 0.57). Heterologous booster shots resulted in increased anti-RBD antibody levels compared with homologous schedules in VAC-n, but not in VAC-ex. NtAbs against Omicron BA.1 were detected in 94%, 75%, and 50% of VAC-ex, VAC-n and UNVAC-ex groups, respectively. For Omicron BA.2, the figures were 97%, 84%, and 40%, respectively. SARS-CoV-2-S-reactive IFN-γ T cells were detected in 73%, 75%, and 64% of VAC-ex, VAC-n and UNVAC-ex, respectively. Median frequencies for both T-cell subsets were comparable across groups. In summary, by April 2022, around half of the VC population had been infected with SARS-CoV-2 and, due to extensive vaccination, displayed hybrid immunity. 相似文献
614.
Dixie Huntley Estela Giménez Lourdes Vázquez María Jesús Pascual Paula Amat María José Remigia Juan Carlos Hernández-Boluda Magdalena García Beatriz Gago Ignacio Torres Carlos Solano de la Asunción Rafael Hernani Ariadna Pérez Eliseo Albert José Luis Piñana Carlos Solano David Navarro 《Transplant infectious disease》2023,25(3):e14065
615.
Guillermo di Girolamo Guillermo A. Keller Lara Beider Claudio D. González María F. González Bagnes Eliseo González M. Cecilia Fornari Roberto A. Diez 《Fundamental & clinical pharmacology》2023,37(3):651-662
Hemax® is an epoetin alfa product developed by Biosidus S.A. in Argentina at the end of the 1980s and has been present in that market since 1991. The initial presentation was a lyophilized powder containing albumin as stabilizer, to best adapt to environmental conditions in developing countries; more recently, a prefilled syringe, albumin-free presentation was developed, since this presentation has become the preferred standard in many markets. The primary objective was to compare the pharmacokinetic profile of different formulations of epoetin alfa after a single subcutaneous administration to healthy volunteers of 40 000 IU of Eprex/Erypo® and Hemax® PFS. This clinical trial was conceived following an open-label, randomized, three-way three-period cross-over balanced, and sequential design. The study was conducted on 24 healthy volunteers. To analyze similarity between Hemax® PFS and the innovator product, Eprex®, area under the curve (AUC) and Cmax of both products have been compared. The 90% CI lower limit for the geometric mean ratios was higher than 80% for any comparisons, and the 90% CI upper limit for these geometric ratios was below 125% for all the comparisons made, thus demonstrating equivalence between both products. The comparison between Hemax® PFS and Eprex® resulted in similar 90% CI for Cmax, AUC(0–120 h) and AUC(0-inf) ratios, all of them within the 80–125% interval, with a power above 95% for each ratio. These findings suggest biosimilar patterns for absorption velocity (with Tmax close to 15 h), absorption extent, and elimination (with an elimination half-life close to 25–30 h for each formulation). 相似文献
616.
Solano de la Asunción Carlos Estela Giménez Juan Carlos Hernández-Boluda María José Terol Eliseo Albert Javier López-Jiménez Valentín García-Gutiérrez Rafael Andreu Dolores García María Laura Fox María José Remigia Paula Amat Carlos Solano David Navarro 《British journal of haematology》2023,200(6):e58-e61
617.
Jorge Camacho Eliseo Albert Joao Zulaica Beatriz Álvarez-Rodríguez Luciana Rusu Beatriz Olea María Jesús Alcaraz Ron Geller Estela Giménez David Navarro 《Journal of medical virology》2023,95(1):e28397
The information provided by SARS-CoV-2 spike (S)-targeting immunoassays can be instrumental in clinical-decision making. We compared the performance of the Elecsys® Anti-SARS-CoV-2 S assay (Roche Diagnostics) and the LIAISON® SARS-CoV-2 TrimericS IgG assay (DiaSorin) using a total of 1176 sera from 797 individuals, of which 286 were from vaccinated-SARS-CoV-2/experienced (Vac-Ex), 581 from vaccinated/naïve (Vac-N), 147 from unvaccinated/experienced (Unvac-Ex), and 162 from unvaccinated/naïve (Unvac-N) individuals. The Roche assay returned a higher number of positive results (907 vs. 790; p = 0.45; overall sensitivity: 89.3% vs. 77.6%). The concordance between results provided by the two immunoassays was higher for sera from Vac-N (ϰ: 0.58; interquartile ranges [IQR]: 0.50−0.65) than for sera from Vac-Ex (ϰ: 0.19; IQR: −0.14 to 0.52) or Unvac-Ex (ϰ: 0.18; IQR: 0.06−0.30). Discordant results occurred more frequently among sera from Unvac-Ex (34.7%) followed by Vac-N (14.6%) and Vac-Ex (2.7%). Antibody levels quantified by both immunoassays were not significantly different when <250 (p = 0.87) or <1000 BAU/ml (p = 0.13); in contrast, for sera ≥1000 BAU/ml, the Roche assay returned significantly higher values than the DiaSorin assay (p < 0.008). Neutralizing antibody titers (NtAb) were measured in 127 sera from Vac-Ex or Vac-N using a S-pseudotyped virus neutralization assay of Wuhan-Hu-1, Omicron BA.1, and Omicron BA.2. The correlation between antibody levels and NtAb titers was higher for sera from Vac-N than those from Vac-Ex, irrespective of the (sub)variant considered. In conclusion, neither qualitative nor quantitative results returned by both immunoassays are interchangeable. The performance of both assays was found to be greatly influenced by the vaccination and SARS-CoV-2 infection status of individuals. 相似文献